Major pharma eyes mid-priced biotech M&A deals in 2013

01/11/2013 | Xconomy

Big drugmakers with expired patents on major products will increasingly depend on mergers and acquisitions to increase sales, according to an analysis from Ernst & Young. Demand is expected to be high for biotech firms in the $5 billion to $20 billion range, particularly for "bolt-on" operations that can contribute to sales immediately.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health